These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 17191946)
21. Histone deacetylase inhibitors: molecular mechanisms of action. Xu WS; Parmigiani RB; Marks PA Oncogene; 2007 Aug; 26(37):5541-52. PubMed ID: 17694093 [TBL] [Abstract][Full Text] [Related]
22. Novel amide derivatives as inhibitors of histone deacetylase: design, synthesis and SAR. Andrianov V; Gailite V; Lola D; Loza E; Semenikhina V; Kalvinsh I; Finn P; Petersen KD; Ritchie JW; Khan N; Tumber A; Collins LS; Vadlamudi SM; Björkling F; Sehested M Eur J Med Chem; 2009 Mar; 44(3):1067-85. PubMed ID: 18672316 [TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitors: a potential new category of anti-tumor agents. Pan LN; Lu J; Huang B Cell Mol Immunol; 2007 Oct; 4(5):337-43. PubMed ID: 17976313 [TBL] [Abstract][Full Text] [Related]
24. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Carew JS; Giles FJ; Nawrocki ST Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867 [TBL] [Abstract][Full Text] [Related]
25. New pyrrole-based histone deacetylase inhibitors: binding mode, enzyme- and cell-based investigations. Mai A; Valente S; Nebbioso A; Simeoni S; Ragno R; Massa S; Brosch G; De Bellis F; Manzo F; Altucci L Int J Biochem Cell Biol; 2009 Jan; 41(1):235-47. PubMed ID: 18834955 [TBL] [Abstract][Full Text] [Related]
26. The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells. Fedier A; Dedes KJ; Imesch P; Von Bueren AO; Fink D Int J Oncol; 2007 Sep; 31(3):633-41. PubMed ID: 17671692 [TBL] [Abstract][Full Text] [Related]
27. 3D-QSAR of histone deacetylase inhibitors as anticancer agents by genetic function approximation. Wagh NK; Deokar HS; Juvale DC; Kadam SS; Kulkarni VM Indian J Biochem Biophys; 2006 Dec; 43(6):360-71. PubMed ID: 17285800 [TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Rahim R; Strobl JS Anticancer Drugs; 2009 Sep; 20(8):736-45. PubMed ID: 19584707 [TBL] [Abstract][Full Text] [Related]
29. 2-Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Jones P; Bottomley MJ; Carfí A; Cecchetti O; Ferrigno F; Lo Surdo P; Ontoria JM; Rowley M; Scarpelli R; Schultz-Fademrecht C; Steinkühler C Bioorg Med Chem Lett; 2008 Jun; 18(11):3456-61. PubMed ID: 18440229 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group. Chen PC; Patil V; Guerrant W; Green P; Oyelere AK Bioorg Med Chem; 2008 May; 16(9):4839-53. PubMed ID: 18397827 [TBL] [Abstract][Full Text] [Related]
31. Targeting histone deacetylases for heart failure. Bush EW; McKinsey TA Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913 [TBL] [Abstract][Full Text] [Related]
32. Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Kazantsev AG; Thompson LM Nat Rev Drug Discov; 2008 Oct; 7(10):854-68. PubMed ID: 18827828 [TBL] [Abstract][Full Text] [Related]
33. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Frew AJ; Johnstone RW; Bolden JE Cancer Lett; 2009 Aug; 280(2):125-33. PubMed ID: 19359091 [TBL] [Abstract][Full Text] [Related]
34. Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling. Chen YD; Jiang YJ; Zhou JW; Yu QS; You QD J Mol Graph Model; 2008 Apr; 26(7):1160-8. PubMed ID: 18061500 [TBL] [Abstract][Full Text] [Related]
35. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Khan N; Jeffers M; Kumar S; Hackett C; Boldog F; Khramtsov N; Qian X; Mills E; Berghs SC; Carey N; Finn PW; Collins LS; Tumber A; Ritchie JW; Jensen PB; Lichenstein HS; Sehested M Biochem J; 2008 Jan; 409(2):581-9. PubMed ID: 17868033 [TBL] [Abstract][Full Text] [Related]
36. Design and campaign synthesis of piperidine- and thiazole-based histone deacetylase inhibitors. Andrews DM; Stokes ES; Carr GR; Matusiak ZS; Roberts CA; Waring MJ; Brady MC; Chresta CM; East SJ Bioorg Med Chem Lett; 2008 Apr; 18(8):2580-4. PubMed ID: 18378449 [TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666 [TBL] [Abstract][Full Text] [Related]
38. Optimization of a series of potent and selective ketone histone deacetylase inhibitors. Pescatore G; Kinzel O; Attenni B; Cecchetti O; Fiore F; Fonsi M; Rowley M; Schultz-Fademrecht C; Serafini S; Steinkühler C; Jones P Bioorg Med Chem Lett; 2008 Oct; 18(20):5528-32. PubMed ID: 18809328 [TBL] [Abstract][Full Text] [Related]
39. Fluoroalkene modification of mercaptoacetamide-based histone deacetylase inhibitors. Osada S; Sano S; Ueyama M; Chuman Y; Kodama H; Sakaguchi K Bioorg Med Chem; 2010 Jan; 18(2):605-11. PubMed ID: 20036560 [TBL] [Abstract][Full Text] [Related]
40. Novel inhibitors of human histone deacetylase (HDAC) identified by QSAR modeling of known inhibitors, virtual screening, and experimental validation. Tang H; Wang XS; Huang XP; Roth BL; Butler KV; Kozikowski AP; Jung M; Tropsha A J Chem Inf Model; 2009 Feb; 49(2):461-76. PubMed ID: 19182860 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]